Stephen P. Anthony

3.3k total citations
53 papers, 1.5k citations indexed

About

Stephen P. Anthony is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stephen P. Anthony has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 20 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stephen P. Anthony's work include Cancer Treatment and Pharmacology (13 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Cancer therapeutics and mechanisms (9 papers). Stephen P. Anthony is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Cancer therapeutics and mechanisms (9 papers). Stephen P. Anthony collaborates with scholars based in United States, United Kingdom and Spain. Stephen P. Anthony's co-authors include Donald Richards, Daniel D. Von Hoff, Svetislava J. Vukelja, Gayle Jameson, David Loesch, Mitesh J. Borad, Peter J. Rosen, David Mallery, Michael Bittner and William Sutherland and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Stephen P. Anthony

52 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen P. Anthony United States	14	881	603	482	368	199	53	1.5k
Gayle Jameson United States	19	944 1.1×	556 0.9×	546 1.1×	399 1.1×	131 0.7×	76	1.6k
Eleni Andreopoulou United States	27	1.4k 1.6×	856 1.4×	634 1.3×	568 1.5×	139 0.7×	90	2.2k
Ying Fan China	23	1.1k 1.2×	697 1.2×	542 1.1×	513 1.4×	125 0.6×	120	1.7k
А. Н. Махсон Russia	15	1.2k 1.4×	397 0.7×	310 0.6×	563 1.5×	112 0.6×	23	1.7k
Shoichiro Ohtani Japan	19	939 1.1×	375 0.6×	371 0.8×	399 1.1×	79 0.4×	92	1.4k
Lourdes Calvo Spain	23	1.2k 1.4×	1.1k 1.8×	518 1.1×	344 0.9×	171 0.9×	102	2.0k
Ernesto Wasserman United States	17	812 0.9×	377 0.6×	418 0.9×	358 1.0×	114 0.6×	35	1.2k
Zhimin Shao China	22	1.1k 1.3×	557 0.9×	516 1.1×	557 1.5×	142 0.7×	90	1.8k
Antonella Argentiero Italy	23	794 0.9×	427 0.7×	596 1.2×	326 0.9×	149 0.7×	48	1.6k
Carmen Belli Italy	20	1.0k 1.1×	401 0.7×	550 1.1×	517 1.4×	113 0.6×	60	1.7k

Countries citing papers authored by Stephen P. Anthony

Since Specialization

Citations

This map shows the geographic impact of Stephen P. Anthony's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen P. Anthony with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen P. Anthony more than expected).

Fields of papers citing papers by Stephen P. Anthony

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen P. Anthony. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen P. Anthony. The network helps show where Stephen P. Anthony may publish in the future.

Co-authorship network of co-authors of Stephen P. Anthony

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen P. Anthony. A scholar is included among the top collaborators of Stephen P. Anthony based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen P. Anthony. Stephen P. Anthony is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saygin, Caner, Girish Venkataraman, Vijayalakshmi Ananthanarayanan, et al.. (2023). Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clinical Cancer Research. 29(16). 3151–3161. 10 indexed citations

Walker, Alison R., Pau Montesinos, Dale L. Bixby, et al.. (2022). Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).. Journal of Clinical Oncology. 40(16_suppl). TPS7071–TPS7071. 3 indexed citations

Zeidner, Joshua F., Daniel J. Lee, Mark G. Frattini, et al.. (2020). Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia. Clinical Cancer Research. 27(1). 60–69. 18 indexed citations

Adjei, Alex A., Muhammad S. Beg, Jason M. Melear, et al.. (2020). 536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours. Annals of Oncology. 31. S469–S469. 1 indexed citations

Zeidner, Joshua F., Daniel J. Lee, Eunice S. Wang, et al.. (2020). Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm. Blood. 136(Supplement 1). 48–50.

Brown, Jennifer R., Ruth Plummer, Todd M. Bauer, et al.. (2017). Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. Experimental Hematology and Oncology. 6(1). 27–27. 8 indexed citations

Cheung, Eric, William J. Edenfield, Bassam Mattar, et al.. (2017). Safety and Pharmacokinetics of Bendamustine Rapid‐Infusion Formulation. The Journal of Clinical Pharmacology. 57(11). 1400–1408. 3 indexed citations

Borad, Mitesh J., Hani M. Babiker, Stephen P. Anthony, et al.. (2015). A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma. Cancer Investigation. 33(5). 172–179. 5 indexed citations

Jameson, Gayle, Emanuel F. Petricoin, Jasgit C. Sachdev, et al.. (2014). A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Research and Treatment. 147(3). 579–588. 57 indexed citations

10.

Ramos, Pilar, Anthony N. Karnezis, William P.D. Hendricks, et al.. (2014). Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). PubMed. 2(1). e967148–e967148. 40 indexed citations

11.

Weiss, Glen J., Jasgit C. Sachdev, Jeffrey R. Infante, et al.. (2014). Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.. Journal of Clinical Oncology. 32(15_suppl). e19005–e19005. 12 indexed citations

12.

Ramanathan, Ramesh K., Peter P. Lee, Joseph W. Leach, et al.. (2013). Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology. 31(4_suppl). 233–233. 3 indexed citations

13.

Stephens, Bret J., Stephen P. Anthony, Haiyong Han, et al.. (2012). Molecular Characterization of a Patient's Small Cell Carcinoma of the Ovary of the Hypercalcemic Type. Journal of Cancer. 3. 58–66. 11 indexed citations

14.

Gordon, Michael S., Lee S. Rosen, David S. Mendelson, et al.. (2012). A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 31(3). 714–723. 26 indexed citations

15.

Weiss, Glen J., Ross C. Donehower, Ramesh K. Ramanathan, et al.. (2012). Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer. Investigational New Drugs. 31(1). 136–144. 41 indexed citations

16.

Cunningham, Casey, Neil Senzer, Joe Stephenson, et al.. (2009). Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer. 9(1). 263–263. 70 indexed citations

17.

Anthony, Stephen P., William L. Read, Peter J. Rosen, et al.. (2008). Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity. Journal of Clinical Oncology. 26(15_suppl). 2531–2531. 8 indexed citations

18.

Sausville, Edward A., Stephen P. Anthony, Lawrence Garbo, et al.. (2007). A phase I study of the safety, tolerability, and pharmacokinetics of intravenous XMT-1001 in patients with advanced solid tumors.. 6. 3 indexed citations

19.

Richards, Donald, Kristi A. Boehm, & Stephen P. Anthony. (2007). Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opinion on Investigational Drugs. 16(7). 1059–1068. 1 indexed citations

20.

Nemunaitis, John, Neil Senzer, Casey Cunningham, et al.. (2006). Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer. Molecular Therapy. 13(6). 1185–1191. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact